Archive · 19 Jan 2026
Granules India Focuses on Injectables and M&A
Granules India is a company that makes medicines and other health products.
They have three main areas they work in: making basic medicine ingredients, creating more complex medicines, and helping other companies develop and make their products.
The company's leader, Priyanka Chigurupati, says they are looking to buy another company to help them make injectable medicines.
They want to make sure these injectables are of very high quality.
They are also investing a lot in research and development to improve their products and processes.
The company has several research centers around the world and plans to spend more on complex medicines in the future.
They are careful with their money and won't spend more than $50 million on any one purchase.
Granules India is focusing on injectables and evaluating potential acquisitions.
The company operates in three core verticals: integrated pharma, complex pharma, and CDMO.
They have eight R&D centers globally and plan to invest heavily in complex generics.
Potential acquisitions for injectables manufacturing may be outside India.
Funding for acquisitions will come from internal cash and possibly debt, with a limit of $50 million.
- Who
- Granules India, led by Executive Director Priyanka Chigurupati
- What
- Expansion into injectables and potential acquisitions
- When
- Currently evaluating opportunities
- Where
- Potential acquisition site may not be in India
- Why
- To differentiate through quality and address market shortages
- Company
- Granules India
- Executive
- Priyanka Chigurupati
- Core Verticals
- Integrated Pharma, Complex Pharma, CDMO
- R&D Centers
- 8 (US, Pune, Hyderabad, Switzerland)
- Potential Acquisition Size
- Up to $50 million
- Key Segments
- Oncology, Peptides, Injectables, ADHD, CNS Opioids
- Funding Options
- Internal Cash, Debt